BFRI (Biofrontera) PEG Ratio: N/A (As of Jun. 28, 2026)


BFRI Biofrontera Inc BFRI
44 GF Score
Price $0.98
GF Value $0.54
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Biofrontera PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Biofrontera's PE Ratio without NRI is 0.00. Biofrontera's 5-Year EBITDA growth rate is 0.00%. Therefore, Biofrontera's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Biofrontera's PEG Ratio or its related term are showing as below:



BFRI's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.67
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Biofrontera  (NAS:BFRI) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Biofrontera PEG Ratio Related Terms


Biofrontera PEG Ratio Historical Data

* Premium members only.

The historical data trend for Biofrontera's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera PEG Ratio Chart

Biofrontera Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Biofrontera Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BFRI vs AKAN, CABR, BIOE: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Biofrontera's PEG Ratio falls into.


BFRI
44GF Score
Biofrontera Inc BFRI
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofrontera PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Biofrontera's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Biofrontera (BFRI) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera stock appears to be overvalued. The current stock price of $0.98 is trading 81.5% above its estimated GF Value™ of $0.54. GuruFocus considers Biofrontera to be Significantly Overvalued.

Key valuation signals for BFRI:

  • PEG Ratio: N/A
  • GF Value™: $0.54 vs. price of $0.98 (81.5% above fair value)
  • GF Score™: 44/100 with 4 warning signs

No single metric tells the full story. See the BFRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biofrontera Business Description

Address 660 Main Street, 1st Floor, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
44GF Score

Get the complete analysis for BFRI

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.98
Price
$0.54
GF Value